Farallon says it's won all desired board seats from Exelixis after shareholder vote
Less than two months after Farallon Capital Management launched a proxy fight to gain control of three seats on cancer biotech Exelixis’ board, it got …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.